Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5277_Библиотеки_им_академика_М_И_Перельмана.pdf
208 Bioactive Glass Materials for Biological Applications
10.9 FUTURE OUTLOOK AND INNOVATION
10.9.1 advancements in material science
The future of bioactive glasses and their industrial compliance and LCA is inter-
twined with ongoing advancements in material science, biomaterials engineering,
and healthcare technologies. Key areas of innovation and future outlook include:
• Advanced Composition Design: Continued research into novel compo-
sitions of bioactive glasses, including the incorporation of bioactive ions,
nanomaterials, and functional additives, aims to enhance bioactivity,
mechanical properties, and therapeutic functionalities.
• Smart and Responsive Materials: Development of smart bioactive
glasses with responsive properties, such as controlled drug release, stimuli-
responsive behaviour, and bioresponsive surfaces, opens new avenues for
targeted therapies, personalized medicine, and regenerative treatments.
• Biocompatibility and Immunomodulation: Advances in understanding
the immune response to biomaterials, surface modications for improved
biocompatibility, and immunomodulatory properties of bioactive glasses
pave the way for immune-informed design strategies and enhanced tissue
integration.
10.9.2 sustainaBle manufacturinG practices
The future of bioactive glasses also emphasizes sustainable manufacturing practices,
environmental stewardship, and circular economy principles. Key trends and initia-
tives include:
• Green Chemistry and Process Innovation: Integration of green chemistry
principles, eco-friendly processing methods, and sustainable manufacturing
practices minimize environmental impact, reduce resource consumption,
and promote eco-efciency.
• Circular Economy Models: Adoption of circular economy models, waste
valorization strategies, and closed-loop material cycles transform waste into
valuable resources, promote material reuse, and support sustainable produc-
tion and consumption patterns.
• Lifecycle Assessment and Environmental Footprinting: Advancements
in lifecycle assessment methodologies, environmental footprinting tools,
and sustainability metrics enable comprehensive analysis of environmental
impacts, resource efciency, and carbon footprint across the entire value
chain.
10.9.3 diGitalization and industry 4.0 inteGration
The digital transformation and integration of Industry 4.0 technologies in bioactive
glass manufacturing and compliance processes are key drivers of future innovation
and efciency gains:
209Challenges for Industrial Compliance and Life Cycle Analysis
• Digital Twin and Simulation: Utilization of digital twin models, simula-
tion tools, and virtual prototyping techniques optimize product design, pro-
cess validation, and performance prediction, accelerating time-to-market
and reducing development costs.
• Data Analytics and Predictive Maintenance: Harnessing big data ana-
lytics, machine learning algorithms, and predictive maintenance strate-
gies improve process control, quality assurance, and equipment reliability,
enhancing productivity and regulatory compliance.
• Supply Chain Visibility and Traceability: Blockchain technology, IoT
sensors, and supply chain management systems provide real-time visibility,
transparency, and traceability across supply chains, ensuring product qual-
ity, regulatory compliance, and risk mitigation.
10.9.4 collaBoration and interdisciplinary research
Collaboration among academia, industry, healthcare providers, and regulatory agen-
cies is essential for driving innovation, addressing complex challenges, and translat-
ing research discoveries into clinical applications:
• Interdisciplinary Research Consortia: Formation of interdisciplinary
research consortia, collaborative partnerships, and innovation hubs foster
knowledge exchange, cross-disciplinary collaborations, and technology
transfer, accelerating innovation and commercialization.
• Regulatory Science and Policy Development: Engagement with regula-
tory agencies, participation in standardization initiatives, and advocacy
for science-based policies promote regulatory harmonization, facilitate
market access, and ensure patient safety and efcacy of bioactive glass
products.
• Global Health Initiatives: Alignment with global health initiatives, sus-
tainable development goals, and patient-centred healthcare models drive
innovation toward affordable, accessible, and equitable healthcare solu-
tions, addressing unmet medical needs and improving healthcare outcomes
worldwide.
In conclusion, the future of bioactive glasses is characterized by continuous innova-
tion, sustainability, digitalization, and collaborative partnerships, shaping a trans-
formative landscape for healthcare technologies, biomaterials engineering, and
patient-centred care.
Continuous innovation in bioactive glass research and development will lead to
the creation of novel compositions, enhanced properties, and expanded functional-
ities, unlocking new possibilities for medical applications. Sustainability will play a
crucial role, with a focus on minimizing environmental impact, optimizing resource
usage, and adopting eco-friendly production processes. Digitalization will revo-
lutionize the eld through the adoption of technologies such as digital twins, data
analytics, and predictive modelling, enabling more efcient product design, manu-
facturing processes, and healthcare delivery.
210 Bioactive Glass Materials for Biological Applications
Collaborative partnerships will foster cross-disciplinary collaborations, knowl-
edge exchange, and technology transfer, accelerating the translation of research nd-
ings into practical applications and commercial products. These partnerships will
bring together expertise from diverse elds, including materials science, biology,
medicine, engineering, and digital technology, to address complex healthcare chal-
lenges and improve patient outcomes.
10.10 CONCLUSION AND RECOMMENDATIONS
10.10.1 key takeaways
The exploration of challenges in industrial compliance and LCA of bioactive glasses
has revealed signicant opportunities for innovation, sustainability, and collabora-
tion in the healthcare and biomaterials sectors. Key takeaways from this analysis
include:
• Regulatory Navigation: Navigating complex regulatory frameworks
requires early engagement, comprehensive documentation, and collabora-
tion with regulatory agencies and industry partners to ensure compliance
and market access.
• Sustainability Imperative: Embracing sustainable manufacturing prac-
tices, circular economy principles, and environmental stewardship is cru-
cial for minimizing environmental impact, enhancing resource efciency,
and meeting global sustainability goals.
• Technological Advancements: Leveraging advancements in material sci-
ence, digitalization, and Industry 4.0 technologies drives innovation, ef-
ciency gains, and quality improvements in bioactive glass manufacturing
and compliance processes.
• Interdisciplinary Collaboration: Fostered collaboration among academia,
industry, healthcare providers, and regulatory agencies is essential for driv-
ing innovation, addressing complex challenges, and translating research
discoveries into clinical applications.
10.10.2 recommendations for future action
Based on the insights gained, the following recommendations are proposed to
advance the eld of bioactive glasses and ensure sustainable growth and compliance:
• Investment in Research and Development: Allocate resources and fund-
ing for research and development initiatives focused on novel compositions,
smart materials, sustainable manufacturing processes, and regulatory sci-
ence to drive innovation and competitiveness.
• Education and Training: Provide education, training, and capacity-
building programmes for industry professionals, researchers, and regula-
tory experts to enhance knowledge, skills, and best practices in industrial
compliance, sustainability, and technology adoption.
211Challenges for Industrial Compliance and Life Cycle Analysis
• Collaborative Networks: Foster collaborative networks, research con-
sortia, and public-private partnerships to facilitate knowledge exchange,
interdisciplinary collaborations, and technology transfer, accelerating the
translation of research into commercial products and clinical solutions.
• Regulatory Harmonization: Advocate for regulatory harmonization,
alignment with international standards, and science-based policies to
streamline regulatory pathways, promote market access, and ensure patient
safety and efcacy of bioactive glass products.
• Sustainability Integration: Integrate sustainability principles, environ-
mental impact assessments, and life cycle analyses into product develop-
ment, manufacturing processes, and supply chain management to promote
environmental responsibility, resource efciency, and circular economy
practices.
• Digital Transformation: Embrace digital transformation, data analyt-
ics, and Industry 4.0 technologies to optimize manufacturing operations,
enhance quality control, and improve regulatory compliance through
real-time monitoring, predictive analytics, and automation.
By implementing these recommendations, stakeholders in the bioactive glass indus-
try can foster innovation, sustainability, and compliance excellence, paving the way
for transformative advancements in healthcare, biomaterials engineering, and patient
care.
Through investment in research and development initiatives, stakeholders can
drive innovation in bioactive glass materials, enabling the development of novel com-
positions, smart materials, and sustainable manufacturing processes. By integrating
sustainability principles into product development, manufacturing operations, and
supply chain management, stakeholders can minimize environmental impact, con-
serve resources, and promote circular economy practices, contributing to a more
sustainable and resilient bioeconomy.
Furthermore, by embracing digital transformation, data analytics, and
Industry4.0 technologies, stakeholders can optimize manufacturing operations,
enhance quality control, and improve regulatory compliance through real-time
monitoring, predictive analytics, and automation. These digital initiatives enable
stakeholders to leverage data-driven insights and advanced technologies to
streamline processes, reduce costs, and ensure consistency and reproducibility in
manufacturing operations, ultimately driving efciency and competitiveness in
the bioactive glass industry.
Overall, by adopting a comprehensive approach that encompasses innovation,
sustainability, and compliance excellence, stakeholders in the bioactive glass
industry can unlock new opportunities for growth, differentiation, and impact.
Through collaborative partnerships, interdisciplinary collaboration, and a com-
mitment to continuous improvement, stakeholders can collectively drive transfor-
mative advancements that benet patients, healthcare providers, and society as a
whole, ultimately advancing the eld of healthcare, biomaterials engineering, and
patient care.
212 Bioactive Glass Materials for Biological Applications
REFERENCES
1. L. L. Hench, “The story of Bioglass®,” J Mater Sci Mater Med, vol. 17, no. 11, pp.967–
978, Nov. 2006, doi: 10.1007/s10856‑006‑0432‑z.
2. M. Montazerian and E. Dutra Zanotto, “History and trends of bioactive glass‑ ceramics,”
J Biomed Mater Res A, vol. 104, no. 5, pp. 1231–1249, May 2016, doi: 10.1002/
jbm.a.35639.
3. A. Shearer, M. Montazerian, J. J. Sly, R. G. Hill, and J. C. Mauro, “Trends and perspec‑
tives on the commercialization of bioactive glasses,” Acta Biomater, vol. 160, pp.14–31,
2023, doi: 10.1016/J.ACTBIO.2023.02.020.
4. F. Baino, “Bioactive glasses and glass‑ceramics,” Ency Mater Tech Ceram Glass, vol.
3, no. 2, pp. V3‑614 –V3‑623, 2021, doi: 10.1016/B978‑0‑12‑803581‑8.12088‑0.
5. H. R. Fernandes, A. Gaddam, A. Rebelo, D. Brazete, G. E. Stan, and J. M. F. Ferreira,
“Bioactive glasses and glass‑ceramics for healthcare applications in bone regenera‑
tion and tissue engineering.,” Materia ls (Basel), vol. 11, no. 12, 2018, doi: 10.3390/
ma11122 53 0.
6. A. C. Profeta and C. Huppa, “Bioactive‑glass in oral and maxillofacial surgery,”
Craniomaxillofac Trauma Reconstr, vol. 9, no. 1, pp. 1–14, 2016, doi: 10.1055/s‑
0035‑1551543.
7. “Global bioactive glass market analysis | size & forecasts.” Accessed: May 22,
2024. [Online]. Available: https://www.globalmarketestimates.com/market‑report/
bioactive‑glass‑market‑3489
8. M. Rizwan, M. Hamdi, and W. J. Basirun, “Bioglass® 45S5‑based composites for bone
tissue engineering and functional applications,” J Biomed Mater Res A, vol. 105, no. 11,
pp.3197–3223, 2017, doi: 10.1002/jbm.a.36156.
9. N. Al‑Harbi etal., “Silica‑based bioactive glasses and their applications in hard tissue
regeneration: a review,” Pharmaceuticals, vol. 14, no. 2, pp.1–20, 2021, doi: 10.3390/
PH1402 0 0 75.
10. H. Yu, J. Peng, Y. Xu, J. Chang, and H. Li, “Bioglass activated skin tissue engineering
constructs for wound healing,” ACS Appl Mater Interfaces, vol. 8, no. 1, pp.703–715,
2016, doi: 10.1021/acsami.5b09853.
11. D. Vukajlovic, J. Parker, O. Bretcanu, and K. Novakovic, “Chitosan based polymer/
bioglass composites for tissue engineering applications,” Mater Sci Eng C, vol. 96,
pp.955–967, 2019, doi: 10.1016/j.msec.2018.12.026.
12. N. A. P. Van Gestel, J. Geurts, D. J. W. Hulsen, B. Van Rietbergen, S. Hofmann, and J.
J. Arts, “Clinical applications of S53P4 bioactive glass in bone healing and osteomy‑
elitic treatment: a literature review,” Biomed Res Int, vol. 2015, p.684826. 2015, doi:
10.1155/2015/684826.
13. M. T. Souza, S. Tansaz, E. D. Zanotto, and A. R. Boccaccini, “Bioactive glass ber‑
reinforced PGS matrix composites for cartilage regeneration,” Mater ials (B asel),
vol. 10, no. 1, p.83. 2017, doi: 10.3390/ma10010083.
14. R. Lin et a l ., “Copper‑incorp orated bioactive glass‑ceram ics inducing a nti‑ in ammatory
phenotype and regeneration of cartilage/bone interface,” Theranostics, vol. 9, no. 21,
pp.6300–6313, 2019, doi: 10.7150/thno.36120.
15. J. Zhou etal., “In vivo and in vitro studies of borate based glass micro‑bers for dermal
re pairing,” Mater Sci Eng C, vol. 60, pp.437–445, 2016, doi: 10.1016/j.msec.2015.11.068.
16. M. H. Kaou, M. Furkó, K. Balázsi, and C. Balázsi, “Advanced bioactive glasses: the
newest achievements and breakthroughs in the area,” Nanomaterials, vol. 13, no. 16,
p.2287, Aug. 2023, doi: 10.3390/NANO13162287.
17. C. H. Kong, C. Stef, Z. Shi, and W. Wang, “Development of mesoporous bioactive
glass nanoparticles and its use in bone tissue engineering,” J Biomed Mater Res B Appl
Biomater, vol. 106, no. 8, pp.2878–2887, 2018, doi: 10.1002/jbm.b.34143.
213Challenges for Industrial Compliance and Life Cycle Analysis
18. S. Lee, A. Matsugaki, T. Kasuga, and T. Nakano, “Development of bifunctional oriented
bioactive glass/poly(lactic acid) composite scaffolds to control osteoblast alignment and
proliferation,” J Biomed Mater Res A, vol. 107, no. 5, pp.1031–1041, 2019, doi: 10.1002/
jbm.a.36619.
19. Y. Li et al., “Bioactive antibacterial silica‑based nanocomposites hydrogel scaf‑
folds with high angiogenesis for promoting diabetic wound healing and skin repair,”
Theranostics, vol. 10, no. 11, pp.4929– 4943, 2020, doi: 10.7150/thno.41839.
20. N. Dey, F. P. Mohny, G. Betsy Reshma, D. Rao, M. Ganguli, and D. Santhiya,
“Bioinspired synthesis of bioactive glass nanocomposites for hyaluronic acid deliv‑
ery to bone and skin,” Int J Biol Macromol, vol. 253, p. 127262.2023, doi: 10.1016/
j.ijbiomac.2023.127262.
21. X. Zhou, N. Sahai, L. Qi, S. Mankoci, and W. Zhao, “Biomimetic and nanostruc‑
tured hybrid bioactive glass,” Biomaterials, vol. 50, no. 1, pp.1–9, 2015, doi: 10.1016/
j.biomateria ls.2015.01.024.
22. Bos, G., 2018. ISO 13485: 2003/2016—medical devices—quality management
systems—requirements for regulatory purposes. In Handbook of Medical Device
Regulatory Affairs in Asia (pp. 153–174). Jenny Stanford Publishing.
23. A. E. Lottes etal., “Navigating the regulatory pathway for medical devices‑a conversa‑
tion with the FDA, clinicians, researchers, and industry experts,” J Cardiovasc Transl
Res, vol. 15, no. 5, pp.927–943, 2022, doi: 10.1007/S12265‑022‑10232‑1.
215
Index
3D printing, 177, 194
Additive manufacturing, 136, 162
Alkaline, 75, 107
Angiogenic, 32, 190
Animal models, 64, 146
Antibacterial, 31, 142
Antibody, 68, 118
Bioactive glass, 3, 21
Bioactive glass-ceramics, 18, 61
Biocompatibility, 119, 139
Bioglass, 4, 181
Biomimetic, 90, 184
Biomineralization, 12, 31
Biosensing, 22, 56
Bone Augmentation, 94, 101
Bone tissue regeneration, 44, 162
Cancer therapy, 24, 96
Cartilage and Ligament Repair, 199
Cell adhesion, 4, 124
Cell proliferation, 5, 129
Cell viability, 10, 28, 130, 201
Clinical Translation, 85, 163
Clinical trials, 64, 70
Composition, 6, 73
Controlled release, 22, 55
Crystallinity, 51, 81
Cytocompatibility, 75, 146
Cytokines, 27, 119
Cytotoxicity, 12, 29
Degradation, 22, 50
Dental restoration, 72, 90
Drug delivery, 54, 95
Encapsulation, 24, 55
Fused Deposition modelling, 143
Hydroxyapatite, 21, 189
Immune response, 27, 112
Infection, 24, 136
Inammatory response, 68, 77
In vitro, 64, 78
Ionic dissolution, 110, 189
Ion release, 114, 195
Lanthanides, 5
Mechanotransduction, 105, 132
Melting-quenching, 98
Microstructure, 60, 122
Multifunctional carriers, 98–99
Multifunctional nanocomposites, 161
Nanomaterials, 37, 208
Natural materials, 166, 167
Nature-inspired materials 12–14
Orthopedic implants, 21, 25
Osteoconductivity, 69, 79
Osteogenesis, 82, 109
Porosity, 116, 130
Quality Assurance, 133, 207
Regulatory challenges, 160, 206
Regulatory frameworks, 182, 200
Regulatory Harmonization, 199, 209
Root canal therapy, 93
Scaffolds, 54, 89. 129, 143
Simulated body uid, 65, 78
Sintering, 53
Sol-gel, 52
Supramolecular chemistry, 175
Surface nishing, 145
Surface hydrolysis, 66
Surface morphology, 57, 58, 59
Sustainability 204, 205
T and B cells, 118
Therapeutics, 24
Transition, 4, 40
Wound healing, 171